Exhibit
10.7.2


 


Certain
identified information has been excluded from the exhibit pursuant to Item 601(b)(10)(iv) because it is both not material and is the
type of information that the registrant treats as private or confidential. Redacted information is indicated by: [***]


 


This second
Amendment to the UNIVERSITY HEALTH NETWORK LICENSE AGREEMENT is made as of the 11th day of July, 2007 (the “Effective
Date”) between the following Parties:


 


UNIVERSITY
HEALTH NETWORK an Ontario corporation incorporated by special statute under the Toronto Hospital Act, 1997, having a principal
office at 190 Elizabeth Street, R. Fraser Elliott Building — Room 1S-417, Toronto, Ontario M5G 2C4


 


(hereinafter
referred to as “UHN”)


 


-AND-


 


AMORFIX
LIFE SCIENCES INC. a Canada corporation with offices located at 3080 Yonge St., Suite 6020, Toronto, Ontario, M4N 3M1, Canada


 


(hereinafter
referred to as the “Licensee”)


 


WHEREAS:


 


(A)            
The Parties entered into a License Agreement dated as of April 4, 2006, (the “License Agreement”), which was amended
on July 13, 2006, pursuant to which the Licensee obtained an exclusive license to the UHN's ownership rights in the Technology as defined
in the License Agreement;


 


(B)             
Subsequent thereto, the parties have recognized that UHN possessed further ownership rights in the Technology that should have
been identified in the original License Agreement;


 


(C)             
Certain Improvements have been identified as originating with UHN and which the parties agree should now be included in the License
Agreement; and


 


(D)            
The parties wish to amend the License Agreement in recognition of these events and to incorporate these features.


 


(E)             
Amorfix agrees upon validation of the URN Epitopes, similar to DSE1, to make Milestone Payments in Accordance with Schedule C;


 






     


     


    

 


NOW
THEREFORE THIS AMENDMENT WITNESSES that in consideration of the premises and mutual agreements and covenants herein contained (the
receipt and adequacy of such consideration being mutually acknowledged by each Party), the Parties covenant and agree as follows:


 


		1.	Replace Schedule
                                            A with Amended Schedule A attached hereto, thereby to add reference to the PCT patent application
                                            filed March 5, 2006, for “Methods and Compositions to Treat and Detect Misfolded SOD1
                                            Mediated Disorders”, to the US counterpart thereof, and to priority applications referenced
                                            therein, and to update the schedule with respect to the originally identified US provisional
                                            application.



 


		2.	Replace Schedule
                                            C with Amended Schedule C attached hereto, thereby to set out the consideration for Improvements
                                            identified in new Schedule D;



 


		3.	Add Schedule
                                            D to identify, as Improvements, the disease specific epitopes designated DSE4 and DSE7.



 


		4.	In Article
                                            2.4, insert -- on Schedule D and -- after “...these Improvements will be included”.



 


New
Article 2.4 now reads:


 


Improvements
by UHN. UHN will notify the Licensee, in writing, of all ALS-related Improvements related to the Technology or arising from the Funded
Research within fourteen (14) days from the date of a UHN Invention Disclosure (“Notice of Disclosure”). Licensee will have
sixty (60) days after receiving the written Notice of Disclosure to notify UHN its intent, in writing, to license said improvement (“Notice
of Intent”). If UHN does not receive a Notice of Intent within sixty (60) days, UHN will be free to dispose of the Improvement
by UHN as it sees fit. After a Notice of Intent has been received, an Amendment shall be made such that these Improvements will be included
on Schedule D and under the definition of Technology and terms hereunder. In the event that the technologies that are not ALS-related
arose from Funded Research, Licensee shall have the first right of refusal to negotiate a new license within sixty (60) days from a written
notice of UHN Invention Disclosure. Any such license shall be on terms and conditions that are consistent with other such licenses
within the industry and satisfactory to UHN.


 


This Amendment
may be executed in as many counterparts as may be necessary or by facsimile and each such counterpart agreement or facsimile so executed
shall be deemed to be an original and such counterparts and facsimile copies together shall constitute one and the same instrument.


 






    -2-


     


    

 


IN WITNESS
WHEREOF, the Parties hereto have executed this Amendment on the date first above written.


 


	UNIVERSITY
    HEALTH NETWORK (UHN)	 
	 	 
	Per:	/s/
    Christopher Paige	 
	Name:	Dr.
    Christopher Paige	 
	Title:
    	Vice
    President Research	 
	 	 
	AMORFIX
    LIFE SCIENCES	 
	 	 
	Per:
    	/s/
    George Adams	 
	Name:
    	Dr.
    George Adams	 
	Title:	President
    and CEO	 




 






    -3-


     


    

 


“AMENDED
SCHEDULE A”


 


[Intentionally
Omitted]


 






    -4-


     


    

 


AMENDED
SCHEDULE C


 


Milestone
Payments


 


	Diagnostic	Payment
	Upfront
    fee upon signing of UHN-IP rights under the Technology and inclusion of any Improvement developed by UHN under Funded Research for
    diagnostic use, where Improvement includes the:

     
	$[***]
	a.	Disease Specific Epitope (DSE/SED)
    DSE 1*;	 
	b.	DSE 4 or DSE 7, upon confirmation
    that antibody thereto binds selectively to misfolded SOD 1	 
	*	“DSE1”
    is synonymous with SEDI	 
	 	.       Detection
    of any DSE in CSF samples in humans where the DSE is DSE 1, DSE 4, DSE 7	$[***]
	a.	Detection
    of any DSE epitope in blood samples where the DSE is DSE 1, DSE 4, DSE 7	$[***]
	b.	First
    Product approval in Canada, USA, Europe or Japan where the Product incorporates any of DSE1, DSE 4, DSE 7 antibody / antibodies	$[***]
	Therapeutic	 
	Upfront
    fee upon inclusion of any UHN-IP rights under the Technology or Improvement developed by UHN under Funded Research for therapeutic
    use	$[***]
	a.	Completion
    of Phase I studies where the DSE is DSE 1, DSE 4 or DSE 7 antibody / antibodies	$[***]
	b.	Completion
    of Phase II studies where the DSE is DSE 1, DSE 4 or DSE 7 antibody / antibodies	$[***]
	c.	Completion
    of Phase III studies where the DSE is DSE 1, DSE 4 or DSE 7 antibody / antibodies	$[***]
	d.	First
    Product approval in Canada, USA, Europe or Japan where the Product incorporates DSE1, DSE4 or DSE7 antibody / antibodies	$[***]



 






    -5-


     


    

 


Buyout
Payments under section 2.2


 


	Diagnostic	Payment
	Upon
    signing of this Agreement	$[***]
	a.	Detection
    of Disease Specific Epitope DSE 1, DSE 4 or DSE 7 in CSF human samples	$[***]
	b.	Detection
    of Disease Specific Epitope DSE 1, DSE 4 or DSE 7 in blood samples	$[***]
	Therapeutic	 
	Upon
    signing of this Agreement	$[***]
	a.	Completion
    of Phase I studies	$[***]
	b.	Completion
    of Phase II studies	$[***]


 


Royalty


 


	Application
    of Technology or Improvements from Funded Research	Percent
    Royalty rate from Net Sales received by the Licensee or sublicensees in each Quarter Yearly Period for all Products and Services
    sold.  Each payment shall be made within thirty (30) days of the end of each Quarter Yearly Period; and,
	DSE
    1, DSE 4 or DSE 7 Diagnostic	[***]%
	DSE
    1 , DSE 4 or DSE 7 Therapeutic	[***]%









 






    -6-


     


    

 


SCHEDULE
D – Improvements


 


[Intentionally
Omitted]


 








    -7-